A Study of Itraconazole in the Prevention of Histoplasmosis, a Fungal Infection, in HIV-Infected Patients
- Conditions
- HIV InfectionsHistoplasmosis
- Registration Number
- NCT00002438
- Lead Sponsor
- Janssen, LP
- Brief Summary
To assess the safety and efficacy of itraconazole versus placebo for prevention of histoplasmosis in HIV-infected patients with CD4 counts \< 150 cells/mm3 who reside where histoplasmosis is endemic. To assess the safety and efficacy of itraconazole for preventing other debilitating fungal infections, such as cryptococcosis, aspergillosis, recalcitrant oropharyngeal or vaginal candidiasis, and recurrent esophageal candidiasis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (7)
Infectious Diseases Research Clinic / Indiana Univ Hosp
🇺🇸Indianapolis, Indiana, United States
Infectious Diseases of Indianapolis
🇺🇸Indianapolis, Indiana, United States
Univ of Missouri at Kansas City School of Medicine
🇺🇸Kansas City, Missouri, United States
Infectious Diseases Association / Research Med Ctr
🇺🇸Kansas City, Missouri, United States
ASCC
🇺🇸Memphis, Tennessee, United States
Dr Michael Threikeld
🇺🇸Memphis, Tennessee, United States
Dr Mark A Pierce
🇺🇸Nashville, Tennessee, United States
Infectious Diseases Research Clinic / Indiana Univ Hosp🇺🇸Indianapolis, Indiana, United States